These findings may be particularly informative for clinical anti-tau trials56 and may encourage future studies on enhancing Klotho protein levels as a therapeutic intervention to slow down the development of tau pathology and dementia in AD. The gene discussed is MAPT; the disease is Alzheimer disease.